HMMR and chronic myelogenous leukemia, BCR-ABL1 positive: ,21 Another serologic screening of a CML cDNA library revealed antibody responses against the receptor for hyaluronan-acid-mediated motility (RHAMM) and the intracellular target M-phase phosphoprotein 11 in patients with CML, and in patients with AML, melanoma, renal cell carcinoma and other malignancies, but not in healthy volunteers or patients with autoimmune diseases.22, 23, 24 The latter indicates that the immune system is also capable of recognizing immunogenic tumour-associated antigens such as RHAMM outside of the allogeneic setting.